Genzyme launches MRD (minimal residual disease) test
This article was originally published in Clinica
Executive Summary
Genzyme Genetics has launched a noninvasive test to detect minimal residual disease (MRD) in patients with B-cell chronic lymphocyte leukaemia (B-CLL). MRD refers to undetectable disease in the blood and bone marrow of leukaemia patients in complete remission.